Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
5-day change
1st Jan Change
9.44
USD
-1.26%
-9.14%
-6.16%
Presenter SpeechMatthew Harrison (Analysts)Great. Thanks for joining us, everybody, for the ne...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Transcript : Vir Biotechnology, Inc., Q1 2024 Earnings Call, May 02, 2024
May. 02
Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q1 Revenue $56.4M, vs. Street Est of $11.7M
May. 02
MT
Vir Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 02
CI
Cytokinetics Appoints Sung Lee as CFO
Apr. 26
MT
Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Chief Financial Officer, Effective May 3, 2024
Apr. 18
CI
Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Executive Vice President, effective May 3, 2024
Apr. 18
CI
Transcript : Vir Biotechnology, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 07:30 AM
Mar. 13
Vir Biotechnology Completes Enrollment in Phase 2 Chronic Hepatitis Delta Trial Ahead of Schedule
Mar. 05
MT
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
Mar. 05
CI
Vir Biotechnology's Q4 Loss Widens, Revenue Declines
Feb. 23
MT
Vir Biotechnology, GSK Terminate Collaboration on Flu
Feb. 22
DJ
Transcript : Vir Biotechnology, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Feb. 22
Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q4 Revenue $16.8M, vs. Street Est of $6.55M
Feb. 22
MT
Vir Biotechnology, Inc. and Glaxo Wellcome UK Limited Mutually Agrees to Terminate Collaboration on the Influenza Program Under the DCA
Feb. 22
CI
Vir Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Feb. 22
CI
Vir Biotechnology, Inc. Announces Phil Pang Will Step Down as Chief Medical Officer
Feb. 20
CI
HC Wainwright Adjusts Vir Biotechnology Price Target to $110 From $85, Maintains Buy Rating
Feb. 14
MT
North American Morning Briefing : Microsoft Kicks -2-
Jan. 30
DJ
JPMorgan Downgrades Vir Biotechnology to Neutral From Overweight, Cuts Price Target to $9 From $23
Jan. 29
MT
Transcript : Vir Biotechnology, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM
Jan. 10
Vir Biotechnology to Eliminate Roles, Close Facilities to Cut Costs
Dec. 13
MT
Vir Biotechnology to cut about 75 jobs, shut some facilities
Dec. 13
RE
Transcript : Vir Biotechnology, Inc. - Special Call
Nov. 13
Transcript : Vir Biotechnology, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Nov. 02
Earnings Flash (VIR) VIR BIOTECHNOLOGY Posts Q3 Revenue $2.6M, vs. Street Est of $8.8M
Nov. 02
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
More about the company
Last Close Price
9.44
USD
Average target price
29.75
USD
Spread / Average Target
+215.15%
Consensus
1st Jan change
Capi.
-6.16% 1.28B +17.96% 44.96B +48.77% 41.85B +1.17% 42.65B -4.27% 29.04B +11.42% 26.08B -21.39% 19.03B +4.86% 12.75B +27.29% 12.06B -3.50% 11.75B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1